Revenue segments as reported by the company.

BD Medical

BD Life Sciences

BD Interventional

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative

Research and development

Acquisition-related integration and restructuring

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Becton, Dickinson and Co.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

BDX surpasses Q1 expectations, eyes growth amid market challenges

Becton, Dickinson and Co. delivered strong Q1 results, driven by the BD2025 strategy and successful product launches across segments.
While facing challenges in market dynamics and inflationary pressures, the company remains focused on margin expansion and operational efficiency.
Strategic investments, disciplined capital deployment, and a robust pipeline position BD for continued growth and performance improvement in FY 2023.

BDX reports strong Q2 performance, raises guidance for growth

Becton, Dickinson and Co. (BDX) demonstrated robust financial performance and strategic progress in Q2 2023, with raised guidance and a focus on long-term growth.
The company's strengths lie in innovation, efficiency, and sustainability initiatives, while facing challenges in operational execution and macroeconomic factors.
Opportunities for BDX include leveraging M&A for growth, capitalizing on healthcare transformation trends, and meeting long-term targets through sustained performance.
Overall, BDX's performance, strengths, challenges, and opportunities position it for continued success and resilience in the evolving healthcare landscape.

BDX reports robust Q3 earnings, focuses on Alaris system growth

BDX's Q3 earnings call highlighted strong financial performance, progress on BD2025 strategy, and strategic product launches.
The company aims to enhance operational efficiency, improve patient care, and drive revenue growth through innovative solutions.
Despite challenges like market backlog and macroeconomic factors, BD remains focused on long-term targets and margin expansion.

BD reports strong Q4 earnings, eyes growth amid challenges

BD's strong performance in Q4 and FY '23 driven by strategic initiatives and new product launches
Challenges in Q1 and macro environment expected to persist, but opportunities in new product launches and margin improvement
Focus on cash flow, margin improvement, and growth drivers to navigate challenges and drive value creation
Confidence in achieving operating margin guidance and strong performance in FY '24

Becton, Dickinson and Co. exceeds Q1 expectations, eyes growth opportunities

BD's Q1 performance was strong, with a focus on innovation and margin improvement initiatives driving robust cash flows.
Raised FY '24 guidance reflects confidence in revenue growth and margin expansion, despite potential challenges like FX moderation.
Opportunities for growth include market entry in molecular diagnostics and strategic capacity conversion in China.

BDX reports robust Q2 earnings, focuses on innovation and growth

Becton, Dickinson and Co. (BDX) delivered a strong Q2 performance, showcasing robust revenue, margin growth, and innovation. While facing challenges in market dynamics, BD remains focused on achieving its operating margin goal and capitalizing on opportunities for revenue acceleration and margin expansion.

BDX excels in Q3 with strong revenue growth and operational efficiency

Becton, Dickinson and Co. (BDX) showcased robust performance in Q3 2024, driven by organic revenue growth and operational excellence. While facing challenges in market dynamics, the company remains focused on innovation and growth strategies to achieve its financial targets and drive shareholder value.

BDX reports robust Q4 earnings, eyes growth amid market complexities

BDX delivered strong financial performance in Q4 2024, showcasing resilience and strategic focus amidst market challenges.
The company's emphasis on growth initiatives, operational excellence, and shareholder value underscores a commitment to sustainable growth.
While facing challenges such as market uncertainties and integration complexities, BD remains poised to leverage opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

FRANKLIN LAKES, N.J. , Dec. 4, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next installment of its BD Innovates series, which will highlight its Pharmaceutical Systems business on Monday, December 11, 2023, at 11:30 am Eastern Time.

BD to Present Next Installment of BD Innovates Series: Spotlight on Pharmaceutical Systems

Archer-Daniels-Midland Company

Automatic Data Processing

American Electric Power Company

Amgen

Atmos Energy

Auburn National Bancorporation

Avnet

Avery Dennison

Best Buy

Blackrock Inc

Badger Meter

Bank of Montreal

Cabot

Cogent Communications Holdings

Canadian Imperial Bank of Commerce

CME Group

Canadian National Railway Company

CNO Financial Group

ChoiceOne Financial Services Inc

CRA International

Chevron

Discover

Dolby Laboratories

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

Dividend Champion, Contender, And Challenger Highlights: Week Of December 3

Company Committed to Support U.S. Health Care Needs FRANKLIN LAKES, N.J. , Nov. 30, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding the U.S. Food and Drug Administration (FDA) Safety Communication on evaluation of certain plastic syringes: Eric Borin, president of BD Medication Delivery Solutions said, "The FDA safety notice does not apply to any BD syringes.

FDA Safety Communication Does Not Impact BD Syringes

Cass Information Systems

Schwab US Dividend Equity ETF

Spire

United Bancorp

United Bankshares

UMB Financial

UniFirst

WesBanco

Dividend growing companies perform better than those that don't increase their payouts consistently. Becton, Dickinson and Company is a dividend king, while UBSI and ADP are approaching king status. December is the last opportunity for companies to announce their yearly dividend increase.

9 Upcoming Dividend Increases, Including A King

Air Products and Chemicals

Cigna

Dover

Johnson & Johnson

Mattel

This month, I've published two pieces about technical analysis — one on Bollinger Bands and another on the Relative Strength Indicator (RSI).

7 Blue-Chip Stocks to Buy for 2024, According to AI

SiteRite™ 9 Ultrasound System Delivers Enhanced Image Quality and Vessel Assessment Tools to Aid in First Attempt IV Insertion Success FRANKLIN LAKES, N.J. , Nov. 30, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices.

BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency

FRANKLIN LAKES, N.J. , Nov. 21, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Ronald (Ron) Silverman, MD, FACS, has been named executive vice president and chief medical officer of BD, effective Dec. 4, 2023.

BD Names Dr. Ronald Silverman as Chief Medical Officer

Acutus Medical

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Eagle Pharmaceuticals

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That Could Blast Off This Quarter - Acutus Medical (NASDAQ:AFIB), Becton Dickinson (NYSE:BDX)

FRANKLIN LAKES, N.J. , Nov. 14, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023 at 8:20 am Eastern Time.

BD to Present at the 6th Annual Evercore ISI HealthCONx Conference

Becton, Dickinson, and Company is a healthcare company with strong fundamentals and a history of dividend growth. The company has shown robust execution of its 2025 strategy, positioning it for sustained growth and innovation in the medical technology space. However, there are risks to the investment, including slower EPS growth, competition, and a lack of margin of safety in the current valuation.

Following The Q4 Results, Becton, Dickinson and Company Is Still A Hold

Merck

NIKE

Agilent Technologies

American Equity Investment Life

Assurant

Cencora Inc

CubeSmart

Emerson Electric

Evergy Inc

Huntington Ingalls Industries

Hormel Foods

Lancaster Colony

Matthews International

McCormick

Motorola Solutions

Nelnet

Royal Gold

Roper Technologies

Snap-on

York Water

Investors were rewarded with 10%+ dividend increases from Snap-on Tools and ADP in the first half of November. Other companies that rewarded investors in the first two weeks of the month were Emerson, which extended its dividend growth streak to 67 years, and utilities Atmos and Evergy. The second half of the month will bring dividend increases from Nike, Merck, Hormel and Agilent, among others.

Nike, Merck Among 13 Companies To Announce Annual Dividend Increases In Second Half Of November

BD's (BDX) overall top line benefits from revenue growth in all its segments and both geographic regions in the fiscal fourth quarter.

BD (BDX) Q4 Earnings In-Line With Estimates, Margins Contract

Disney

Tesla

U.S. equities fell midday ahead of comments from Fed Chair Jerome Powell that could offer clues about the future of monetary policy. The Dow, S&P 500, and Nasdaq were all lower.

Midday Movers: Disney Rises, Tesla and Becton Dickinson Fall

Becton, Dickinson and Company (NYSE:BDX ) Q43 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Greg Rodetis - Senior Vice President, Treasurer and Head of Investor Relations Tom Polen – Chairman, President and Chief Executive Officer Chris DelOrefice – Executive Vice President and Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Vijay Kumar - Evercore ISI Larry Biegelsen - Wells Fargo Travis Steed - Bank of America Matt Miksic - Barclays Operator Hello, and welcome to BD's Fourth Quarter and Full Year Fiscal 2023 Earnings Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at (800) 688-7339 for domestic and area code 1-40220-1347 for International.

Becton, Dickinson and Company (BDX) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About Becton Dickinson (BDX) Q4 Earnings

Becton Dickinson reported fourth-quarter revenue above Wall Street estimates on Thursday, helped by strong demand for its drug-delivery devices and surgical equipment.

BD beats quarterly revenue estimates on strong demand for medical devices

Execution of BD 2025 Strategy Driving Durable, Broad-Based Growth Q4 revenue of $5.1 billion increased 6.8% as reported and 5.9% on a currency-neutral basis Q4 revenue from base business (which excludes COVID-only diagnostic testing) grew 7.3% as reported, 6.3% currency-neutral or 7.0% organic Q4 GAAP and adjusted diluted EPS from continuing operations of $0.53 and $3.42, respectively FY23 revenue of $19.4 billion increased 2.7% as reported and 4.5% on a currency-neutral basis FY23 revenue from base business grew 5.1% as reported, 7.0% currency-neutral or 5.8% organic FY23 GAAP and adjusted diluted EPS from continuing operations of $5.10 and $12.21, respectively Company issues FY24 guidance including 5.75% organic revenue growth at midpoint of 5.25% to 6.25% range; announces 52nd consecutive year of dividend increases FRANKLIN LAKES, N.J. , Nov. 9, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fourth quarter and full year of fiscal 2023, which ended September 30, 2023.

BD Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

News for Becton, Dickinson and Co. Stock (BDX)